Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.000001 par value
-
Shares outstanding
-
15,729,081
-
Total 13F shares
-
16,492,025
-
Share change
-
+409,818
-
Total reported value
-
$339,874,510
-
Put/Call ratio
-
0%
-
Price per share
-
$20.60
-
Number of holders
-
92
-
Value change
-
+$9,470,657
-
Number of buys
-
35
-
Number of sells
-
36
Institutional Holders of Neurogene Inc. - Common Stock, $0.000001 par value (NGNE) as of Q4 2025
As of 31 Dec 2025,
Neurogene Inc. - Common Stock, $0.000001 par value (NGNE) was held by
92 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
16,492,025 shares.
The largest 10 holders included
SAMSARA BIOCAPITAL, LLC, Redmile Group, LLC, RTW INVESTMENTS, LP, Casdin Capital, LLC, EcoR1 Capital, LLC, BAKER BROS. ADVISORS LP, BlackRock, Inc., Trails Edge Capital Partners, LP, TORONTO DOMINION BANK, and VANGUARD GROUP INC.
This page lists
92
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.